Wall Street analysts predict that Prestige Consumer Healthcare Inc. (NYSE:PBH) will announce $232.05 million in sales for the current quarter, Zacks reports. Four analysts have made estimates for Prestige Consumer Healthcare's earnings. The highest sales estimate is $234.10 million and the lowest is $229.80 million. Prestige Consumer Healthcare reported sales of $241.55 million in the same quarter last year, which indicates a negative year over year growth rate of 3.9%. The business is scheduled to issue its next quarterly earnings report on Thursday, February 4th.
According to Zacks, analysts expect that Prestige Consumer Healthcare will report full year sales of $926.00 million for the current financial year, with estimates ranging from $925.00 million to $927.90 million. For the next year, analysts expect that the business will report sales of $939.88 million, with estimates ranging from $929.70 million to $953.80 million. Zacks Investment Research's sales calculations are a mean average based on a survey of analysts that cover Prestige Consumer Healthcare.
Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.72 by $0.06. The company had revenue of $237.42 million during the quarter, compared to the consensus estimate of $227.43 million. Prestige Consumer Healthcare had a return on equity of 13.81% and a net margin of 15.84%. The firm's revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned $0.68 earnings per share.
Several equities research analysts have recently issued reports on PBH shares. Zacks Investment Research lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "hold" rating and set a $39.00 price target for the company. in a research note on Monday, October 12th. DA Davidson lowered their price target on Prestige Consumer Healthcare from $45.00 to $39.00 and set a "neutral" rating on the stock in a report on Friday, November 6th. BMO Capital Markets upped their target price on shares of Prestige Consumer Healthcare from $106.00 to $112.00 and gave the stock a "market perform" rating in a research report on Friday, November 6th. TD Securities boosted their price objective on shares of Prestige Consumer Healthcare from $115.00 to $125.00 and gave the stock a "buy" rating in a report on Friday, November 6th. Finally, CIBC increased their target price on Prestige Consumer Healthcare from $100.00 to $103.00 and gave the company a "neutral" rating in a report on Monday, November 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and two have assigned a buy rating to the stock. The company currently has an average rating of "Hold" and a consensus price target of $72.43.
Shares of NYSE:PBH opened at $36.13 on Friday. The company has a current ratio of 2.24, a quick ratio of 1.35 and a debt-to-equity ratio of 1.32. The stock's fifty day simple moving average is $35.13 and its two-hundred day simple moving average is $37.61. Prestige Consumer Healthcare has a 1-year low of $27.40 and a 1-year high of $46.12. The stock has a market cap of $1.81 billion, a PE ratio of 12.08, a price-to-earnings-growth ratio of 2.76 and a beta of 0.75.
A number of large investors have recently modified their holdings of PBH. Advisor Group Holdings Inc. purchased a new position in shares of Prestige Consumer Healthcare in the 1st quarter valued at $62,000. Envestnet Asset Management Inc. grew its holdings in Prestige Consumer Healthcare by 6.1% during the second quarter. Envestnet Asset Management Inc. now owns 25,909 shares of the company's stock worth $973,000 after acquiring an additional 1,497 shares during the period. SG Americas Securities LLC increased its holdings in shares of Prestige Consumer Healthcare by 46.2% during the 2nd quarter. SG Americas Securities LLC now owns 28,298 shares of the company's stock valued at $1,063,000 after purchasing an additional 8,945 shares in the last quarter. BBVA USA Bancshares Inc. raised its position in shares of Prestige Consumer Healthcare by 8.4% in the second quarter. BBVA USA Bancshares Inc. now owns 17,693 shares of the company's stock worth $665,000 after acquiring an additional 1,364 shares during the period. Finally, First Trust Advisors LP acquired a new position in Prestige Consumer Healthcare in the 2nd quarter worth about $2,306,000.
Prestige Consumer Healthcare Company Profile
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) healthcare products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Featured Article: What is a Reverse Stock Split?
Get a free copy of the Zacks research report on Prestige Consumer Healthcare (PBH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Stocks that Insiders Love
An insider trade occurs when a corporate executive (such as a CEO, CFO or COO) that has non-public information about a company buys or sells shares of that company's stock. Company insiders are required by law to regularly report their stock purchases and sales to the SEC.
Tracking a company's insider trades is a metric that can be used to identify the direction that the company's executives believes that the company is headed. If a number of insiders purchase more shares of their company, they may believe that the company will have strong future earnings and that the share price will increase in the near future.
For example, if Microsoft's CEO, CFO and COO all recently purchased additional shares of Microsoft stock, that would be an indication that there could be unreported news that may positively effect Microsoft's stock price in the near future.
This slideshow lists the 15 companies that have had the highest levels of insider buying within the last 180 days.
View the "15 Stocks that Insiders Love".